ReviewToxicology reports2025
The antioxidant potential of bacoside and its derivatives in Alzheimer's disease: The molecular mechanistic paths and therapeutic prospects.
Review in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bacopa monnieri and Alzheimer's disease: mechanistic convergence, cognitive outcomes and translational perspectives.Inflammopharmacology · 2026Review
- The Role ofNutrients · 2025Review
- Apigenin mitigates oxidative stress, neuroinflammation, and cognitive impairment but enhances learning and memory in aluminum chloride-induced neurotoxicity in rats.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system disorders are likely to have a substantial effect on the worldwide healthcare demands of humanity in this era. Alzheimer's disease (AD) is a senile decay of neurons. Extracellular beta-amyloid accumulation and intracellular tau hyperphosphorylation are two key characteristics of the pathogenesis of AD. Because of the multifactorial character of many disorders, new medicine-based psychoactive treatments have had limited success. As a result, there is a growing demand for innovative products that can target different receptors and improve behavioral abilities on their own or in combination with established treatments. In recent years, both industrialized and developing countries have seen a surge in herbal products based on traditional knowledge. According to recent research, bacoside and its congeners can dramatically lower the build-up of amyloid-β plaques, which are a defining feature of AD. This decrease is explained by bacoside's capacity to regulate β-secretase activity, which lowers the production of amyloid-β. Ayurveda is a medical science that focuses on the use of naturally occurring plant products to treat ailments. Many neuroprotective plants are said to be found in Ayurveda. The key physiological dysfunctions linked to tau aggregates, which contribute to dementia and behavioral inconsistencies, include the formation of reactive oxygen species, augmented neuronal swelling, and neurotoxicity. Here, we have focused on bacopa as an anti-Alzheimer medication. Bacoside A, Baccoside B, Apigenin, Betullinic acid, etc. are the pharmacologically active congeners of Brahmi belonging to several chemical families. In this review, the neuroprotective properties, pharmacological effectiveness, and molecular mechanism of bacoside scaffolds against AD have been discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.